Old Web
English
Sign In
Acemap
>
authorDetail
>
Christopher Walker
Christopher Walker
Incyte
Placebo
Capecitabine
Ruxolitinib
Internal medicine
Chemotherapy regimen
3
Papers
72
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
2018
Investigational New Drugs
Herbert Hurwitz
Eric Van Cutsem
Johanna C. Bendell
Manuel Hidalgo
Chung-Pin Li
Marcelo Garrido Salvo
Teresa Macarulla
Vaibhav Sahai
Ashwin Reddy Sama
Edward W Greeno
Kenneth H. Yu
Chris Verslype
Fitzroy Dawkins
Christopher Walker
Jason Clark
Eileen M. O’Reilly
Show All
Source
Cite
Save
Citations (51)
Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
2017
Journal of Clinical Oncology
Herbert Hurwitz
Eric Van Cutsem
Johanna C. Bendell
Manuel Hidalgo
Chung-Pin Li
Marcelo Garrido
Teresa Macarulla
Vaibhav Sahai
Ashwin Reddy Sama
Edward Greeno
Kenneth H. Yu
Chris Verslype
Fitzroy W. Dawkins
Christopher Walker
Jason Clark
Eileen Mary OReilly
Show All
Source
Cite
Save
Citations (14)
JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.
2015
Journal of Clinical Oncology
Eileen Mary OReilly
Christopher Walker
Jason Clark
Kimberli J. Brill
Fitzroy Dawkins
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (7)
1